| An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells PA Nikitin, CM Yan, E Forte, A Bocedi, JP Tourigny, RE White, MJ Allday, ... Cell host & microbe 8 (6), 510-522, 2010 | 252 | 2010 |
| Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes C Ciferri, S Chandramouli, D Donnarumma, PA Nikitin, MA Cianfrocco, ... Proceedings of the National Academy of Sciences 112 (6), 1767-1772, 2015 | 179 | 2015 |
| Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody S Chandramouli, C Ciferri, PA Nikitin, S Caló, R Gerrein, K Balabanis, ... Nature communications 6 (1), 8176, 2015 | 118* | 2015 |
| Metabolic stress is a barrier to Epstein–Barr virus-mediated B-cell immortalization MAL Karyn McFadden, Amy Y. Hafez, Rigel Kishton, Joshua E. Messinger, Pavel ... PNAS, doi: 10.1073/pnas.1517141113, 2016 | 115* | 2016 |
| Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection AM Price, J Dai, Q Bazot, L Patel, PA Nikitin, R Djavadian, PS Winter, ... Elife 6, e22509, 2017 | 72 | 2017 |
| The DNA damage response in viral-induced cellular transformation PA Nikitin, MA Luftig British journal of cancer 106 (3), 429-435, 2012 | 62 | 2012 |
| Mitogen-Induced B-Cell Proliferation Activates Chk2-Dependent G1/S Cell Cycle Arrest P Nikitin, A Price, K McFadden, C Yan, M Luftig Plos One, 2014 | 45 | 2014 |
| In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539 HD Patel, P Nikitin, T Gesner, JJ Lin, DT Barkan, C Ciferri, A Carfi, ... Antimicrobial agents and chemotherapy 60 (8), 4961-4971, 2016 | 34 | 2016 |
| At a crossroads: human DNA tumor viruses and the host DNA damage response PA Nikitin, MA Luftig Future virology 6 (7), 813-830, 2011 | 32 | 2011 |
| C1s inhibition by BIVV009 (Sutimlimab) prevents complement-enhanced activation of autoimmune human B cells in vitro PA Nikitin, EL Rose, TS Byun, GC Parry, S Panicker The Journal of Immunology 202 (4), 1200-1209, 2019 | 27 | 2019 |
| Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein JM DiMuzio, BC Heimbach, RJ Howanski, JP Dowling, NB Patel, ... Vaccine: X 8, 100098, 2021 | 11 | 2021 |
| IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA. 1 and BA. 2 PA Nikitin, JM DiMuzio, JP Dowling, NB Patel, JL Bingaman-Steele, ... Science immunology 7 (75), eabl9943, 2022 | 10 | 2022 |
| Epstein-Barr virus induces adhesion receptor CD226 (DNAM-1) expression during primary B-cell transformation into lymphoblastoid cell lines L Grossman, C Chang, J Dai, PA Nikitin, DD Jima, SS Dave, MA Luftig Msphere 2 (6), 10.1128/msphere. 00305-17, 2017 | 8* | 2017 |
| Methods of treating autoimmune and alloimmune disorders G Parry, PA Nikitin, S Panicker US Patent App. 15/739,622, 2018 | 5 | 2018 |
| IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation JP Dowling, PA Nikitin, F Shen, H Shukla, JP Finn, N Patel, C Swider, ... Mabs 15 (1), 2212673, 2023 | 3 | 2023 |
| Methods of inducing complement activity S Panicker, S Moore, PA Nikitin, T Byun, G Parry US Patent 11,192,944, 2021 | 3 | 2021 |
| G101 studies at the oncogenic virus/host interface: dynamic regulation of Epstein-Barr virus-mediated B cell immortalization M Luftig, P Nikitin, C Yan, E Forte, J Tourigny, A Price, S Dave JAIDS Journal of Acquired Immune Deficiency Syndromes 62, 58, 2013 | 2 | 2013 |
| 823 IMM20059, a novel anti-EPN1 antibody, in combination with atezolizumab significantly enhances tumor regression in the B16. F10 syngeneic melanoma model compared to anti-PD … J Dowling, P Nikitin, C Swider, C Nicolescu, H Shukla, J Bingaman-Steele, ... J Immunother 10 (2), A1-A1595, 2022 | 1 | 2022 |
| Antibody cocktail against sars-cov-2 spike protein MK Robinson, P Nikitin, MJ Morin, J Dimuzio, R Howanski, JP Dowling US Patent App. 18/493,744, 2024 | | 2024 |
| Il-38-specific antibodies MK Robinson, K Lundgren, B Harman, PA Nikitin, JP Dowling US Patent App. 17/631,102, 2022 | | 2022 |
Micah LuftigDuke UniversityVerified email at duke.edu
